Geron Corporation (GERN) Stock Up Upon Announcement of December Conference Presentations


Shares of Geron Corporation (NASDAQ:GERN) are up in early trading as the company has announced that their CEO and President, John A. Scarlett, M.D. will be presenting at investor conferences in early December. These conferences include:

The Piper Jaffray 27th Annual Healthcare Conference in New York at 8:30 a.m. ET on Wednesday, December 2, 2015.
The Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015.

Both conferences will be available as webcasts availalbe via the links above. It should be interesting to see what Scarlett has to say during these talks.

The stock is up 8.24% or $0.37 after the news, hitting $4.86 per share. About 683,337 shares traded hands. GERN has risen 11.14% since April 27, 2015 and is uptrending. It has outperformed by 12.03% the S&P500.

The institutional sentiment increased to 1.35 in Q2 2015. Its up 0.28, from 1.07 in 2015Q1. The ratio improved, as 14 funds sold all Geron Corporation shares owned while 34 reduced positions. 27 funds bought stakes while 38 increased positions. They now own 71.89 million shares or 6.44% more from 67.54 million shares in 2015Q1.

Opaleye Management Inc. holds 3.11% of its portfolio in Geron Corporation for 1.83 million shares. Doheny Asset Management Ca owns 235,500 shares or 0.45% of their US portfolio. Moreover, Carl Domino Inc has 0.14% invested in the company for 48,100 shares. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.14% in the stock. Qs Investors Llc, a New York-based fund reported 2.02 million shares.

Geron Corporation is a clinical stage biopharmaceutical firm focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company has a market cap of $768.96 million. The Firm operates in one segment, the discovery and development of therapeutic products for oncology. It currently has negative earnings. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation.